Economic evaluation examines GLP-1RA pricing and affordability for obesity treatment in Medicare, implying cost-effectiveness concerns.
This economic evaluation examines the 10-year US pricing and affordability for glucagon-like peptide-1 receptor agonists (GLP-1RAs) for obesity treatment in Medicare.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: